B cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B-cell lymphoma.
B cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B-cell lymphoma.
复制标题
DOI：
10.1309/ajcpgr8bg4jdvowr
复制
发表时间：
2012-05
影响因子：
3.5
通讯作者：
Brinkman RR
中科院分区：
文献类型：
--
作者：
Bashashati A;Johnson NA;Khodabakhshi AH;Whiteside MD;Zare H;Scott DW;Lo K;Gottardo R;Brinkman FS;Connors JM;Slack GW;Gascoyne RD;Weng AP;Brinkman RR
尽管对弥漫性大B细胞淋巴瘤（DLBCL）生物学的理解有了进展，但只有基于临床的国际预后指数（IPI）常规用于诊断时的风险分层。为了找到新的预后标志物，我们使用我们实验室开发的自动化多参数数据分析方法分析了229例诊断DLBCL样本的流式细胞术数据。通过使用开发的自动化数据分析管道，我们确定了229例病例中的71例，其中超过35%的B细胞具有高侧向散射（SSC）特征，这是一个反映内部细胞复杂性的参数。这种高SSC B细胞特征与较差的总生存期和无进展生存期相关（分别为P = 0.001和P = 0.01），并且在多变量考克斯回归分析中仍然是总生存期的重要预测因素（IPI，P = 0.001;高SSC，P = 0.004;利妥昔单抗，P = 0.53）。这项研究表明，高SSC之间的B细胞可以作为一个有用的生物标志物，以确定患者的DLBCL复发的高风险。这是特别令人感兴趣的，因为这种生物标志物在大多数临床实验室中很容易获得，而不会显著改变现有的常规诊断策略或产生额外的成本。
Despite advances in the understanding of diffuse large B-cell lymphoma (DLBCL) biology, only the clinically based International Prognostic Index (IPI) is used routinely for risk stratification at diagnosis. To find novel prognostic markers, we analyzed flow cytometric data from 229 diagnostic DLBCL samples using an automated multiparameter data analysis approach developed in our laboratory. By using the developed automated data analysis pipeline, we identified 71 of 229 cases as having more than 35% B cells with a high side scatter (SSC) profile, a parameter reflecting internal cellular complexity. This high SSC B-cell feature was associated with inferior overall and progression-free survival (P = .001 and P = .01, respectively) and remained a significant predictor of overall survival in multivariate Cox regression analysis (IPI, P = .001; high SSC, P = .004; rituximab, P = .53). This study suggests that high SSC among B cells may serve as a useful biomarker to identify patients with DLBCL at high risk for relapse. This is of particular interest because this biomarker is readily available in most clinical laboratories without significant alteration to existing routine diagnostic strategies or incurring additional costs.